CX-5461

Product Name: CX-5461

Synonyms: CX-5461;2-(4-Methyl-1,4-diazepan-1-yl)-N-((5-Methylpyrazin-2-yl)Methyl)-5-oxo-5H-benzo[4,5]thiazolo[3,2-a][1,8]naphthyridine-6-carboxaMide;2-(Hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo-5H-benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide;CX-5461/CX5461;2-(Hexahydro-4-Methyl-1H-1,4-diazepin-1-yl)-N-[(5-Methyl-2-pyrazinyl)Methyl]-5-oxo-5H-benzothiazolo[3,2-a][1,8]napht;5H-Benzothiazolo[3,2-a][1,8]naphthyridine-6-carboxamide, 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo-

CAS: 1138549-36-6

MF: C26H28N8O2S

MW: 516.61792

Product Categories: apis

density 1.45

Appearance : White powders

Purity : 99%

Package : 1kg/foil bag

Product Description:

CX-5461 is an inhibitor of rRNA synthesis, selectively inhibits Pol I-driven transcription of rRNA with IC50 of 142 nM in HCT-116, A375, and MIA PaCa-2 cells, has no effect on Pol II, and possesses 250- to 300-fold selectivity for inhibition of rRNA transcription versus DNA replication and protein translation.

In vitro :

CX-5461 is found to selectively inhibit rRNA synthesis (Pol I IC50=142 nM; Pol II IC50 > 25 μM; selectivity ~200-fold) in the HCT-116 cells. Selective inhibition of rRNA synthesis by CX-5461 is confirmed in two other human solid tumor cell lines; melanoma A375 (Pol I IC50 = 113 nM; Pol II IC50 > 25 μM) and pancreatic carcinoma MIA PaCa-2 (Pol I IC50=54 nM; Pol II IC50 ~25 mM). CX-5461 possesses 250- to 300-fold selectivity for inhibition of rRNA transcription versus DNA replication and protein translation. CX-5461 exhibits broad antiproliferative potency in a panel of cancer cell lines in human cancer cell lines, but has minimal effect on viability of nontransformed human cells. The median EC50 across all tested cell lines is 147 nM, yet all normal cell lines have EC50 values of approximately 5, 000 nM. Evaluation of the antiproliferative dose response for HCT-116, A375, and MIA PaCa-2 cell lines yield EC50 values of 167, 58, and 74 nM. CX-5461 induces autophagy and senescence in solid tumor cancer cells, rather than apoptosis, through a p53-independent process.

In vivo :

CX-5461 is orally bioavailable and demonstrates in vivo antitumor activity against human solid tumors in murine xenograft models. CX-5461 demonstrates significant MIA PaCa-2 TGI with TGI equal to 69% on day 31, comparable to that of gemcitabine (63% TGI). Gemcitabine is a positive control which is administered intraperitoneally once every 3 days at 120 mg/kg. Likewise, CX- 5461 demonstrates significant A375 TGI with TGI equal to 79% on day 32.

Related DNA/RNA Synthesis Products :

SCR7 CAS : 1533426-72-0

Blasticidin S HCl CAS : 42437-50-3 / CAS : 3513-03-9

YK-4-279 CAS: 1037184-44-3

Cisplatin CAS : 15663-27-1

GEMCITABINE HCL CAS : 122111-03-9

Oxaliplatin CAS : 63121-00-6

Bleomycin Sulfate CAS: 9041-93-4

Gemcitabine CAS: 95058-81-4

Fluorouracil (5-Fluoracil, 5-FU) CAS: 51-21-8

Carboplatin CAS: 41575-94-4

BV6 CAS : 1001600-56-1

Enzalutamide (MDV3100) CAS: 915087-33-1

Everolimus (RAD001) CAS: 159351-69-6

Dapagliflozin CAS: 461432-26-8

Dapagliflozin Intermediate1 CAS: 461432-22-4

Veliparib (ABT-888) CAS: 912444-00-9

Sorafenib Tosylate CAS: 475207-59-1